Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focused on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in May 2012 and is headquartered in Kansas City, KS.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
14
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Cingulate Inc market cap is $67.48M.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Cingulate Inc 52 week high is $11.89 as of November 21, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Cingulate Inc 52 week low is $3.16 as of November 21, 2026.
Cingulate Inc stock price today is $4.51.
Cingulate Inc stock price yesterday was $5.26.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Cingulate Inc's P/E ratio is -1.61.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Cingulate Inc P/B ratio is 3.2058.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Cingulate Inc 50-day moving average is $4.81.